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Leishmaniasis is initiated when sandflies inject the extracellular promastigote 
form of the parasite into the skin.  Promastigotes are rapidly phagocytized, after 
which they transform into the intracellular amastigote form. The multiplication 
of the latter within macrophages leads to clinical disease. Treatment of leishman- 
iasis  is primarily  with pentavalent  antimonials,  parenteral  and potentially toxic 
drugs  with  a  10-25%  failure  rate.  The  inosine  analogue  formycin  B  (FOB) 
inhibits  multiplication  of  promastigotes  (1-3)  and  is  leishmanicidal  to  both 
antimony-sensitive  and  antimony-resistant  amastigotes  within  human  macro- 
phages in vitro (4).  FoB is also leishmanicidal  to Leishmania donovani amastigotes 
in infected hamsters after either intraperitoneal  (1) or oral administration  (J. D. 
Berman et al., Exp. Parasitol.  In press). Biochemical studies of the metabolism of 
FoB in promastigotes revealed that this compound is initially converted to its 5'- 
nucleotide,  formycin  B  5'-monophosphate  (FoB-MP),  which  is  subsequently 
metabolized to adenosine nucleotide analogues of formycin A (FoA) that become 
incorporated into RNA (2,  3).  The FoA nucleotides or FoA incorporation  into 
RNA are  believed to  be responsible  for  the  cytotoxic effects of FoB towards 
promastigotes. 
The present study was undertaken  to determine the metabolism and mecha- 
nism  of action  of FoB in  amastigotes  within  cultured  human  macrophages,  a 
model that is comparable to the clinical situation. In addition, the metabolism of 
FoB in uninfected human macrophages and in free amastigotes was investigated. 
Materials and Methods 
Mono-dispersed  Leishmania  amastigotes  of cutaneous  strains WR 401 (Iran),  WR 227 
and WR 420 (Panama), and WR 338 (Dominican Republic) were obtained from foot pads 
* Supported in part by grants to D. V. S. from the UNDP/World Bank/WHO Special Programme 
for  Research  and Training in Tropical  Diseases and  the  Rockefeller  Foundation.  P.  R.  received 
partial support from U. S. Public Health Service (USPHS) training grant GM 07546. 
* To whom reprint requests should be addressed. 
252  J. Exp. MED. © The Rockefeller University Press • 0022-1007/83/07/0252/06 $1.00 
Volume 158  July 1983  252-257 BERMAN  ET  AL.  BRIEF  DEFINITIVE REPORT  253 
of infected BALB/c mice (5).  Human macrophages were derived from monocytes of 
peripheral blood of normal volunteers by 6 d of in vitro cultivation as monolayers in 2- 
cm  ~ plastic wells and infected as previously described (5). To infect macrophages, ~  1.5 
X 10  b mono-dispered amastigotes were added to each culture well, which contained ~  105 
macrophages. After 4 h at 35°C, cultures were washed twice with 1 ml of Hank's buffered 
saline solution (HBSS; Gibco Laboratories, Grand Island, NY) to remove nonphagocytized 
parasites. Specified concentrations of [SH]FoB (1.9 Ci/mmol; ICN Pharmaceuticals) were 
added in  1 ml of medium consisting of RPMI  1640 (Gibco Laboratories) with 50 U/ml 
penicillin, 50 #g/ml streptomycin, and  10% heat-inactivated fetal calf serum.  Infected 
and noninfected cultures were maintained at 35 °C in the presence of [SH]FoB for specified 
times after which the media was aspirated and the monolayer of cells was washed four 
times with 1 ml HBSS at ambient temperature. Each experiment utilized 11 wells, one of 
which was used to count the number of organisms and/or macrophages after Wrights/ 
Giemsa staining (5). The other wells in an experimental group were processed in a cold 
room as follows: The HBSS in one well was aspirated and replaced with 0.6 ml of 0.6 M 
trichloroacetic acid (TCA) and the macrophages were scraped into the acid. The HBSS 
in the second well was aspirated, the TCA suspension from the first well was added, and 
the macrophages were again scraped into the acid. This process was repeated until all 
macrophages within an experimental group were obtained in a single TCA suspension. 
To insure complete recovery, the entire process was  repeated with  0.1  ml  cold TCA 
which was then combined with the first suspension. The suspension was centrifuged at 
10,000 g  for  1 min  (0°C).  The supernatant  was  neutralized by extraction with  tri-n- 
octylamine in  Freon  113 (7);  the acid-insoluble fraction was washed with three 0.1-ml 
portions  of 0.3  M  TCA  (0°C)  and  once  with  0.2  ml  of 95%  EtOH  (-20°C).  For 
experiments with mono-dispersed amastigotes, 1.2 X 10  s cells (strain 227) were incubated 
for 16 h at 35°C in 6 ml of culture medium that contained 0.2 uM [SH]FoB. After the 
cells were harvested by centrifugation and washed with HBSS, acid-soluble and -insoluble 
fractions were prepared (2). Analyses of the metabolites of FoB and of the incorporation 
of FoA into RNA were performed as previously described (2). 
Results 
When human macrophages infected with Leishmania strain 401 were incubated 
for 8 h with 0.2 #M [~H]FoB, high performance liquid chromatography (HPLC) 
analysis of the acid-soluble extract gave four radioactive peaks in addition to FoB 
(Fig.  1).  These peaks were identified as  FoB-MP,  FoA-MP,  FoA-DP, and FoA- 
TP,  the  latter being the predominant  metabolite.  The same  metabolites  were 
found in uninfected macrophage controls, but they were present in significantly 
lower amounts (Fig.  1). 
Fig. 2 shows the kinetics of accumulation of FoB metabolites in both infected 
and uninfected macrophages over a 20-h period of exposure to 0.2 #M [3H]FoB. 
With  infected cells,  the  nucleotide  metabolites accumulated  to maximal  levels 
within 4-8 h  and showed a  slight decrease after 20 h  of exposure. Throughout 
the period, FoA was progressively incorporated into RNA.  No incorporation of 
radioactivity into DNA could be detected. The pattern of FoB metabolism was 
similar  in  uninfected  cells  except  for  the  much  lower  level  of  metabolites 
throughout the period of exposure (Fig. 2B). 
Human  macrophages  infected  with  a  number  of  Leishmania  strains  were 
exposed to 0.04 and 0.2 #M [3H]FoB for 16 h. These concentrations correspond 
to the ECs0 and  EC90 values for elimination of amastigotes from infected mac- 
rophages after 6 d  (4). Mono-dispersed amastigotes were also exposed to 0.2 uM 
[~H]FoB and uninfected macrophages were exposed to 0.2 #M and  10 uM [~H] 254  BERMAN  ET  AL.  BRIEF  DEFINITIVE REPORT 
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F]GtJRE  1.  HPLC of FoB metabolites in acid-soluble extracts from 1.25 x  105 macrophages 
infected with ~ 1.25 x  105 Leishmallia  amastigotes (strain WR 401) (open bars) and  1.25 x 
105 uninfected  macrophages (solid bars), after an 8-h exposure to 0.2 #M [~Hl-formycin B. 
The metabolites were separated  on  a  Partisil SAX column  (4.6  X 250  ram) as previously 
described (2). The histograms indicate the radioactivity in each 3.0-ml fraction. 
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FoB.  The  latter  represents  the  ECs0  for  cytolysis of uninfected  macrophages 
after  6  d  (4).  Table  I  shows  the  total  FoA  nucleotides  present  in  cell  extracts 
expressed  as  pmol per  106  macrophages or  amastigotes;  where  measured,  the 
amount of FoA incorporated  into  RNA is also provided.  The pertinent  results 
derived from these experiments are as follows: First, when infected macrophages 
were  exposed  to  0.2  uM  FoB  there  was  an  excellent  linear  correlation  (r  2 = 
0.977) between the total number ofamastigotes in the macrophage cultures (i.e., 
parasite  burden)  and  the  amount  of  FoA  nucleotides  formed.  Second,  free 
amastigotes synthesized FoA nucleotides from FoB in a manner similar to infected 
macrophages. Although the levels of metabolites may be artifactually low because 
the  obligate  intracel]ular  organisms  were  in  an  unnatural  environment,  the 
experimental confirms that the metabolites are indeed formed by the amastigotes. 
Third,  the  amount  of  FoA  metabolites  in  the  intracellular  amastigotes  was 
correlated  with  the  concentration  of FoB  to  which  the  infected  macropbages 
were exposed. At 0.2 ~M FoB, the levels of FoA metabolites in amastigotes were BERMAN  ET  AL.  BRIEF  DEFINITIVE  REPORT  255  5Iy°  B 
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FIGURE  2.  Accumulation  of formycin  metabolites in  (A)  macrophages  infected  with Leish- 
ma,ia  amastigotes (strain  WR  401)  and  (B)  uninfected  macrophages  during  treatment  with 
0.2  #M  [SH]-formycin  B.  Metabolite  levels were  determined  by  HPLC  as  in  Fig.  1.  FoA 
incorporation  into RNA  was determined  as previously described (2). A  FoB-MP;  ~7, FoA-MP; 
l-q, FoA-DP; (3, FoA-TP; O,  FoA incorporation  into RNA. 
TABLE  I 
Formycin A metabolites and incorporation into RNA in infected and uninfected macrophages and 
in free a mastigotes* 
FoB concen-  Parasite 
Experimental group  tration  burden 
FoA nucleotides  RNA incorporation 
Macro-  Amasti-  Macro-  Amasti- 
phages  gotes  phages  gotes 
Macrophages infected 
with: 
strain 420 
strain 338 
strain 227 
strain 420 
strain 401 
strain 227 
strain 338 
Free amastigotes 
Uninfected macro- 
phages 
Uninfected macro- 
phages 
a m a stigotes 
per macro-  pmol/lO n  pmol/lO 6  pmol/lO 6  pmol/lO 6 
~'Vl  phage  cells  cells  cells  cells 
(average) 
0.04  2  4.1  2.1  0.72  0.36 
0.04  7  5.5  0.8  --*  --* 
0.2  I  4.1  3.2  1.00  0.95 
0.2  2  8.9  4.2  2.49  1.22 
0.2  3  25.6  8.2  --*  --* 
0.2  5  36.7  7.2  --*  --* 
0.2  7  62.5  8,8  --*  --* 
0.2  --  --  1.4  --*  --* 
0.2  --  0.9  i  --  0.05 t  -- 
10.0  --  22.0 !  --  1.10 !  -- 
'~ Cells were exposed to [SH]FoB for 16 h. Parasite burden was determined by counting the number of amastigotes 
in  100 macrophages and dividing by  100. The  levels of radiolabeled metabolites and incorporation into RNA 
were determined as described in Materials and Methods. FoA nucleotides refers to the sum of FoA-MP, FoA-DP 
and FoA-TP.  Levels of metabolites in amastigotes were determined by subtracting metabolite levels in uninfected 
controls from the levels in infected macrophages and dividing by the parasite burden. 
* Not determined. 
! Average of four determinations. 
! Average of two determinations. 256  BERMAN  ET  AL.  BRIEF  DEFINITIVE  REPORT 
three- to fivefold higher than when 0.04 ~M FoB was used. Likewise, the amount 
of FoA  metabolites in  uninfected  macrophages  was dose-related:  the  levels of 
metabolites  in  cells  treated  with  10  ~M  FoB  were  "-~25-fold  higher  than  in 
macrophages treated  with 0.2 #M FoB.  Last, and perhaps  most important,  the 
amount  of FoA metabolites that  were formed in  uninfected  macrophages  was 
far less than that formed in infected macrophages, or even in individual amasti- 
gotes. 
Discussion 
The  results  described  here  demonstrate  that  Leishmania  amastigotes  within 
cultured human  macrophages metabolize FoB in the same manner  as do extra- 
cellular promastigote forms (2, 3). The nucleoside is converted to FoB-MP, FoA- 
MP, FoA-DP, and FoA-TP, the latter representing  -~70% of the total metabo- 
lites; further, FoA is incorporated into RNA. No other metabolites were observed 
nor was incorporation into DNA detectable. There was an excellent correlation 
between  the  parasite  burden  and  the  amount  of  FoA  metabolites  formed, 
indicating  that  the  intracellular  parasites  are  responsible  for  the  metabolic 
conversions.  In  promastigotes,  the  anti-leishmanial  activity  of FoB  has  been 
associated with its conversion to cytotoxic nudeotides of FoA or incorporation 
of FoA into RNA or both (2, 3). The experiments described here correlate the 
killing of amastigotes within macrophages with the synthesis of FoA nucleotides. 
That is, the levels of FoA nucleotides formed in amastigotes and the efficacy of 
FoB in eliminating  the  organisms  within  macrophages  are both related  to  the 
concentration of the drug used. 
It has been reported  that  FoB is not phosphorylated  in  mammalian  cells (8) 
and  is  remarkably  nontoxic  in  animals  (9).  We  show  here  that  uninfected 
macrophages do in fact metabolize FoB in a manner qualitatively similar to that 
of Leishmania.  However, at levels of FoB necessary to eliminate amastigotes from 
infected macrophages,  the amount of metabolites formed in uninfected macro- 
phages  is  low, and  the drug  has no visibly apparent  deleterious effects on the 
macrophages. When concentrations of FoB (10 #M) were used that were 50-fold 
higher  than  the  ECg0 for elimination  of amastigotes,  significant  levels of FoA 
metabolites  were  formed  in  uninfected  macrophages;  at  this  concentration, 
~50% of the macrophages undergo cytolysis after a  6-d exposure to the drug. 
Although we have not yet determined the extent to which other cells are affected 
by FoB, these results with infected human macrophages suggest that a sufficient 
therapeutic  index  exists  to  warrant  serious  consideration  of FoB  as  an  anti- 
leishmanial agent in humans. 
Summary 
Formycin  B is metabolized by cutaneous Leishmania amastigotes within cul- 
tured human macrophages to give formycin B 5'-monophosphate and formycin 
A 5'-mono-,  di-, and triphosphates. Formycin A is also incorporated  into RNA. 
The activity of formycin B against amastigotes was correlated with the levels of 
formycin A  metabolites formed in the parasites. Uninfected macrophages also 
convert formycin B into the same products,  but the levels are markedly  lower BERMAN  ET  AL.  BRIEF  DEFINITIVE  REPORT  257 
than  those  seen  in  infected macrophages.  The results suggest  that  a  sufficient 
therapeutic  index  exists  to  warrant  consideration  of formycin  B  as  an  anti- 
leishmanial drug in humans. 
We thank L. S. Lee for excellent technical assistance. 
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